Test Price
650 AED✅ Home Collection Available
Cultured AFB Antitubercular Drug Susceptibility Testing — Ethionamide (DST) in UAE | 650 AED | 2026 DHA Guidelines
تحليل حساسية المتفطرة السلية للإيثيوناميد (الزراعة واختبار الحساسية للأدوية) في الإمارات | 650 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
الملخص التنفيذي: يقدم هذا التحليل المخبري المعتمد من هيئة الصحة بدبي (DHA) تقييمًا دقيقًا لحساسية المتفطرة السلية (Mycobacterium tuberculosis) تجاه عقار الإيثيوناميد (Ethionamide) باستخدام تقنية الفلورة الآلية (Automated Fluorescent Technology). يُعد هذا الفحص أساسيًا في توجيه علاج السل المقاوم للأدوية المتعددة (MDR-TB) وفقًا للمعايير السريرية لعام 2026. جميع النتائج صادرة عن مختبر حاصل على شهادة ISO 9001:2015، مع خدمة سحب منزلي معتمدة تشمل سلسلة تبريد صارمة، ودعم استشاري هاتفي بعد الفحص لضمان فهم النتائج وتطبيقها سريريًا.
Clinical Overview
The Cultured AFB Antitubercular Drug Susceptibility Testing for Ethionamide (DST) is a definitive phenotypic assay that determines whether a patient's Mycobacterium tuberculosis complex isolate is susceptible or resistant to ethionamide — a critical second-line agent in multidrug-resistant tuberculosis (MDR-TB) regimens. This ISO 9001:2015-accredited test leverages automated fluorescent detection technology (BACTEC MGIT 960) to deliver quantitative susceptibility results within 21 days, enabling clinicians to tailor effective, resistance-guided anti-TB therapy.
اختبار حساسية المتفطرة السلية للإيثيوناميد هو فحص ظاهري نهائي يُحدد ما إذا كانت عزلة المتفطرة السلية لدى المريض حساسة أو مقاومة للإيثيوناميد — وهو عامل علاجي أساسي من الخط الثاني في أنظمة علاج السل المقاوم للأدوية المتعددة. يعتمد هذا الاختبار المعتمد من ISO 9001:2015 على تقنية الكشف الفلوري الآلي لتقديم نتائج كمية خلال 21 يومًا.
| Parameter | Our Test — Automated Fluorescent (MGIT 960) | Conventional Proportion Method (LJ Media) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity; Quantitative MIC determination | ~95% Sensitivity; Semi-quantitative interpretation |
| Methodology | Automated Fluorescent Detection (BACTEC MGIT 960 SIRE DST) | Manual Proportion Method on Löwenstein-Jensen solid media |
| Turnaround Time | 21 Days | 28–42 Days |
Physician Insight & Safety Protocol
A Note from Dr. PRABHAKAR REDDY, DHA-Licensed Clinical Pathologist (License No. 61713011)
"As a clinician with decades of experience managing complex mycobacterial infections, I emphasize that ethionamide susceptibility results must always be correlated with the patient's full clinical picture — including radiographic findings, prior treatment history, and molecular resistance markers. No single laboratory value can replace comprehensive clinical judgment. Please remember that drug susceptibility testing guides therapy but does not replace the physician's duty to monitor for adverse effects such as ethionamide-induced hepatotoxicity, neurotoxicity, or gastrointestinal intolerance throughout the treatment course."
⚠ Medication Safety Warning
DO NOT discontinue any prescribed antitubercular medication — including ethionamide, isoniazid, rifampicin, pyrazinamide, ethambutol, or any second-line agent — without explicit consultation with your treating physician. Abrupt cessation of anti-TB therapy can precipitate drug resistance, treatment failure, and life-threatening clinical deterioration.
Exclusion Criteria & Emergency Red Flags
Sample Rejection Criteria:
- Non-viable or contaminated mycobacterial cultures
- Insufficient pure growth for inoculum preparation
- Specimens submitted in non-sterile, unsealed containers
- Isolates not confirmed as M. tuberculosis complex by prior identification testing (e.g., MPT64 antigen, molecular probe)
- Broken cold chain during transport (temperature deviation beyond 2–8°C for over 4 hours)
Patient ER Red Flags — Seek Immediate Medical Attention:
- Hemoptysis (coughing up blood) exceeding 30 mL in 24 hours
- Acute-onset pleuritic chest pain with dyspnea
- Sudden visual disturbance or blurred vision (possible ethionamide optic neuropathy)
- Jaundice, dark urine, or right upper quadrant pain (hepatotoxicity warning)
- Confusion, seizures, or severe peripheral neuropathy
UAE Regulatory Compliance & Accreditation
This laboratory service is fully compliant with Federal Decree-Law No. 41 of 2024 (Article 87) governing clinical diagnostic facilities in the UAE, the Communicable Disease Surveillance (CDS) Law 2026 with specific provisions for minor patients, and the UAE Personal Data Protection Law (PDPL) ensuring strict data privacy. Our facility holds ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 9834453. All testing personnel are DHA-licensed and adhere to MOHAP-mandated proficiency testing programs.
2026 Methodology & Clinical Coding
Primary Methodology: Automated Fluorescent Detection using the BACTEC MGIT 960 system with SIRE Drug Susceptibility Testing protocol. This liquid-culture-based, fluorometric platform detects oxygen consumption by viable mycobacteria in the presence of ethionamide at critical concentrations, delivering quantitative susceptibility interpretation. The methodology is complemented — not replaced — by molecular resistance testing (e.g., line probe assays, whole genome sequencing for ethA, inhA promoter region, and ndh mutations) per 2026 WHO consolidated guidelines for MDR-TB diagnostics.
ICD-10-CM (2026)
Z16.342
Resistance to other specified antimycobacterial drugs
ICD-10-CM (2026)
A15.0
Respiratory tuberculosis, bacteriologically confirmed
ICD-10-CM (2026)
Z11.1
Encounter for screening for respiratory tuberculosis
LOINC Code:
50416-1 — Mycobacterium tuberculosis complex Ethionamide susceptibility method (Automated Fluorescent)
https://loinc.org/50416-1/
Specimen Requirements & Logistics
Sample Type:
Submit pure growth of Mycobacterium tuberculosis complex on appropriate media (Löwenstein-Jensen slant or Middlebrook 7H11 agar) in a sterile, screw-capped, leak-proof container sealed within a secondary plastic biohazard bag. Ship refrigerated at 2–8°C via certified cold-chain courier. Alternatively, when this DST is ordered in conjunction with AFB culture or Mycobacteria identification tests, the pure growth obtained in our laboratory from previously submitted specimens will be directly processed for antitubercular sensitivity without requiring a separate sample submission.
Specimen Matrix
Pure Bacterial Isolates
Collection Window
Daily by 3:30 PM
Turnaround Time
21 Days
Patient Preparation
No special preparation required
Patient FAQ & Clinical Guidance
Q1: What is the Ethionamide DST test and why has my doctor ordered it?
Snippet Answer: The Ethionamide Drug Susceptibility Test determines whether your tuberculosis bacteria are effectively killed by ethionamide — a critical second-line antibiotic reserved for multidrug-resistant TB treatment — thereby guiding your physician toward a precisely targeted, resistance-informed therapeutic regimen.
Ethionamide is a cornerstone agent in MDR-TB protocols. Without susceptibility confirmation, there is a significant clinical risk of prescribing an ineffective drug, which can prolong infectivity, worsen lung damage, and promote further resistance. Your doctor has ordered this test to ensure that every medication in your treatment plan is scientifically validated to work against your specific strain of M. tuberculosis.
س1: ما هو اختبار حساسية الإيثيوناميد ولماذا طلبه طبيبي؟
اختبار حساسية الإيثيوناميد يحدد ما إذا كانت بكتيريا السل لديك تُقتل بفعالية بواسطة الإيثيوناميد — وهو مضاد حيوي أساسي من الخط الثاني مخصص لعلاج السل المقاوم للأدوية المتعددة — مما يوجه طبيبك نحو نظام علاجي دقيق ومبني على معلومات المقاومة الدوائية.
Q2: How long does it take to receive the ethionamide DST results and what do the terms "Sensitive" and "Resistant" mean?
Snippet Answer: Results are reported within 21 calendar days from the date of pure culture receipt; "Sensitive" indicates ethionamide effectively kills your TB bacteria at standard dosing, while "Resistant" means the drug is clinically ineffective and alternative agents must be substituted.
The 21-day window reflects the biological growth rate of M. tuberculosis — one of the slowest-growing human pathogens — and cannot be accelerated without compromising accuracy. An "Intermediate" result may occasionally be reported, indicating partial susceptibility that requires dose adjustment or combination therapy optimization under specialist guidance.
س2: كم من الوقت يستغرق الحصول على نتائج اختبار حساسية الإيثيوناميد وماذا تعني المصطلحات "حساس" و"مقاوم"؟
تُصدر النتائج في غضون 21 يومًا تقويميًا من تاريخ استلام العينة النقية؛ "حساس" يعني أن الإيثيوناميد يقتل بكتيريا السل بفعالية بالجرعات المعيارية، بينما "مقاوم" يعني أن الدواء غير فعال سريريًا ويجب استبداله بعوامل علاجية بديلة.
Q3: Do I need to stop taking my current tuberculosis medications before undergoing this DST?
Snippet Answer: No — you must continue all prescribed anti-TB medications without interruption; this is performed on a laboratory-cultured isolate and your adherence to therapy has absolutely no impact on the technical accuracy of the susceptibility result.
Stopping medications prematurely — even for a few days — can trigger bacterial regrowth, worsen clinical symptoms, and increase the risk of developing additional drug resistance. The sample for this DST is either a pure culture already growing in the laboratory or a fresh specimen processed independently; your medication schedule remains entirely separate from the testing process.
س3: هل يجب علي التوقف عن تناول أدوية السل الحالية قبل الخضوع لهذا الاختبار؟
لا — يجب عليك الاستمرار في تناول جميع أدوية السل الموصوفة دون انقطاع؛ يتم إجراء هذا الاختبار على عزلة مزروعة مخبريًا والتزامك بالعلاج ليس له أي تأثير على الدقة الفنية لنتيجة اختبار الحساسية.
Clinical Intent & Referring Specialist Guidance
This ethionamide DST serves three distinct clinical pathways: (1) General Physicians utilize results to confirm or revise empiric MDR-TB regimens during initial treatment planning; (2) Primary Care Doctors employ susceptibility data to monitor community-level resistance trends and trigger specialist referrals when ethionamide resistance is detected; and (3) Clinical Laboratory Scientists interpret phenotypic patterns alongside genotypic markers (ethA, inhA, ndh) to produce integrated, clinically actionable microbiology reports compliant with 2026 UAE National Tuberculosis Program standards.
Note: Anti-Aging Specialists, Medical & PhD Researchers, and Forensic Investigators may also engage this assay for research protocols, epidemiological surveillance, and medico-legal investigations respectively, under separate institutional review board (IRB) approval pathways.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians